Novantrone mitoxantrone inhibitor of DNA replication: Phase III data; marketed to treat hormone refractory prostate cancer and nonlymphocytic leukemia

IMNX reported preliminary results of a 194-patient Phase III study conducted in Europe (see Technology Briefing, BioCentury Part I). Patients received

Read the full 210 word article

How to gain access

Continue reading with a
two-week free trial.